Jeremy M. Shefner

15.8k total citations · 1 hit paper
206 papers, 8.5k citations indexed

About

Jeremy M. Shefner is a scholar working on Neurology, Genetics and Cellular and Molecular Neuroscience. According to data from OpenAlex, Jeremy M. Shefner has authored 206 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Neurology, 81 papers in Genetics and 41 papers in Cellular and Molecular Neuroscience. Recurrent topics in Jeremy M. Shefner's work include Amyotrophic Lateral Sclerosis Research (126 papers), Neurogenetic and Muscular Disorders Research (81 papers) and Parkinson's Disease Mechanisms and Treatments (32 papers). Jeremy M. Shefner is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (126 papers), Neurogenetic and Muscular Disorders Research (81 papers) and Parkinson's Disease Mechanisms and Treatments (32 papers). Jeremy M. Shefner collaborates with scholars based in United States, Canada and United Kingdom. Jeremy M. Shefner's co-authors include Merit Cudkowicz, Christian Krarup, Michael W. Levine, David Schoenfeld, Seward B. Rutkove, Hiroshi Mitsumoto, Mamede de Carvalho, Elizabeth M. Raynor, Ryuji Kaji and Eric L. Logigian and has published in prestigious journals such as Science, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Jeremy M. Shefner

194 papers receiving 8.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Electrodiagnostic criteria for diagnosis of ALS

2008 800 citations Hiroshi Mitsumoto, Jeremy M. Shefner et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeremy M. Shefner United States	52	5.0k	3.2k	1.8k	1.8k	932	206	8.5k
Robert G. Miller United States	46	6.9k 1.4×	3.4k 1.1×	1.5k 0.8×	1.5k 0.8×	488 0.5×	114	9.9k
Mamede de Carvalho Portugal	49	7.1k 1.4×	4.2k 1.3×	1.7k 0.9×	1.3k 0.7×	449 0.5×	377	9.8k
Reinhard Dengler Germany	59	6.8k 1.4×	2.1k 0.6×	2.0k 1.1×	2.8k 1.5×	429 0.5×	378	12.4k
Leonard H. van den Berg Netherlands	48	6.0k 1.2×	3.3k 1.0×	2.4k 1.3×	1.9k 1.1×	623 0.7×	177	8.8k
Phil Hyu Lee South Korea	48	5.1k 1.0×	2.0k 0.6×	2.0k 1.1×	2.3k 1.3×	645 0.7×	351	10.4k
Alexander Storch Germany	53	4.0k 0.8×	1.2k 0.4×	3.4k 1.9×	3.0k 1.6×	663 0.7×	328	10.4k
Mark B. Bromberg United States	41	3.3k 0.7×	2.0k 0.6×	1.2k 0.6×	1.3k 0.7×	896 1.0×	169	5.8k
Zachary Simmons United States	44	4.5k 0.9×	1.9k 0.6×	1.5k 0.8×	1.4k 0.8×	468 0.5×	185	7.2k
Isao Date Japan	47	3.2k 0.6×	1.6k 0.5×	2.7k 1.5×	2.6k 1.4×	913 1.0×	440	9.2k
Hiroshi Mitsumoto United States	62	10.1k 2.0×	6.0k 1.9×	4.0k 2.2×	2.4k 1.3×	520 0.6×	252	15.2k

Countries citing papers authored by Jeremy M. Shefner

Since Specialization

Citations

This map shows the geographic impact of Jeremy M. Shefner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy M. Shefner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy M. Shefner more than expected).

Fields of papers citing papers by Jeremy M. Shefner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy M. Shefner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy M. Shefner. The network helps show where Jeremy M. Shefner may publish in the future.

Co-authorship network of co-authors of Jeremy M. Shefner

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy M. Shefner. A scholar is included among the top collaborators of Jeremy M. Shefner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy M. Shefner. Jeremy M. Shefner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gotkine, Marc, David Schoenfeld, Jeremy M. Shefner, et al.. (2025). Akt Activation With IPL344 Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open‐Label Study. Muscle & Nerve. 71(6). 1032–1042.

Rudnicki, Stacy A., Stuart Kupfer, Fady I. Malik, et al.. (2025). Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 26(7-8). 812–820.

Berry, James D., Sabrina Paganoni, Matthew Harms, et al.. (2024). Access for ALL in ALS: A large‐scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosis. Muscle & Nerve. 70(6). 1140–1150. 1 indexed citations

Bedlack, Richard, Daragh Heitzman, & Jeremy M. Shefner. (2024). A Worsening Problem in ALS: Insurance Barriers Between Drug Approvals and Patient Access. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas). 5(1). 1 indexed citations

Shefner, Jeremy M., Stuart Kupfer, Fady I. Malik, et al.. (2023). Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 25(1-2). 162–169.

Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2023). Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS. Journal of Medical Economics. 26(1). 488–493. 2 indexed citations

Hannaford, Andrew, Nathan Pavey, Mehdi van den Bos, et al.. (2022). 2277 Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis. Abstracts. A3.2–A3. 9 indexed citations

Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2022). MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24(3-4). 304–310. 3 indexed citations

Hannaford, Andrew, Nathan Pavey, Mehdi van den Bos, et al.. (2021). Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis. Annals of Neurology. 89(5). 979–986. 82 indexed citations

10.

Kiernan, Matthew C., Steve Vucic, Kevin Talbot, et al.. (2020). Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology. 17(2). 104–118. 178 indexed citations

11.

Meng, Lisa, Stacy A. Rudnicki, Noah Lechtzin, et al.. (2019). Correlation between Slow Vital Capacity Measured in the Home and in the Clinic for Patients with Amyotrophic Lateral Sclerosis (P4.4-002). Neurology. 92(15_supplement). 2 indexed citations

12.

Vliet, Erwin A. van, Anand M. Iyer, Jasper J. Anink, et al.. (2019). Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. Journal of Neuropathology & Experimental Neurology. 79(3). 266–276. 23 indexed citations

13.

Smith, Richard, Eric A. Macklin, Kathleen Myers, et al.. (2018). Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self‐report scale (Center for Neurologic Study Bulbar Function Scale). European Journal of Neurology. 25(7). 907–907. 31 indexed citations

14.

Ratti, Elena, James D. Berry, Nazem Atassi, et al.. (2014). Predictors of Outcome in Amyotrophic Lateral Sclerosis (P2.076). Neurology. 82(10_supplement). 1 indexed citations

15.

Cudkowicz, Merit, Leonard H. van den Berg, Jeremy M. Shefner, et al.. (2013). Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. The Lancet Neurology. 12(11). 1059–1067. 166 indexed citations

16.

Hammond, Edward R., Carolyn Young, Adriano Chiò, et al.. (2013). Evaluation of a Health State Staging System Defined by Loss of Independence in Amyotrophic Lateral Sclerosis: Assessment in a Second Dataset. Oxford University Research Archive (ORA) (University of Oxford). 1 indexed citations

17.

Shefner, Jeremy M., et al.. (2006). Revised statistical motor unit number estimation in the Celecoxib/ALS trial. Muscle & Nerve. 35(2). 228–234. 35 indexed citations

18.

Kamel, Freya, David M. Umbach, Howard Hu, et al.. (2005). Lead Exposure as a Risk Factor for Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases. 2(3-4). 195–201. 88 indexed citations

19.

Kamel, Freya, David M. Umbach, Theodore L. Munsat, et al.. (2002). Lead Exposure and Amyotrophic Lateral Sclerosis. Epidemiology. 13(3). 311–319. 128 indexed citations

20.

Shefner, Jeremy M., et al.. (1999). Reducing intersubject variability in motor unit number estimation. Muscle & Nerve. 22(10). 1457–1460. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact